What does a reportable test actually cost you?
Ask most laboratories what a test costs and they will quote the reagent price. But a released result is the sum of many things, and the parts nobody counts are usually the ones eating the margin.
A planned cost tells you what a test should consume. The real stock draws tell you what it did. The gap between them is where a lab finds the money it has been losing without knowing.
Most attempts at lab costing stop at the plan. Someone works out what a test should cost, writes it down, and treats that figure as the truth. But a planned cost is a theory. It says what the test consumes when everything goes right: no repeats, no wastage, no reagent issued in the wrong quantity, no controls burnt beyond what the run needed. Reality rarely cooperates. The cost a test actually carries is decided not by the plan but by what the lab actually drew from stock to produce the result. The gap between the two is where a laboratory either confirms it is on target or discovers it has been quietly losing money.
A planned cost on its own cannot find that gap, because it has nothing to compare itself against. It is a number with no feedback. To make costing useful, you need both halves: what the test was expected to consume, and what it actually did.
A planned cost is built on assumptions, and assumptions drift. The reagent price you costed against last quarter has moved. The technician issued a slightly larger volume than the plan allowed. A batch of flagged samples triggered repeats that doubled the consumables on those runs. A control was run more often than budgeted because an analyser was misbehaving. None of these show up against a planned figure, because the plan does not watch what happens. It states an intention and then looks away.
The result is a comforting number that nobody has tested against reality. The lab believes a test costs what the plan says, prices on that belief, and only finds out it was wrong when the margins fail to appear. By then the loss is months old and impossible to trace to a cause.
The reason labs stop at the plan is that measuring actual cost is hard. To know what a test really consumed, you would have to tie every stock draw, every issued reagent, every burnt control, every repeat, and every wasted unit back to the specific tests it produced. That means reconciling the stores ledger against the instrument logs against the result record, by hand, continuously. It is the kind of work that is technically possible and practically never done, because it would consume a person full time and still lag behind reality.
So the actual cost stays invisible. The lab has a plan and a bank balance, and nothing in between to connect them.
Veona Cost Per Reportable Test measures actual cost from the consumption that really happened. Because component costs are drawn straight from stock at weighted-average cost, every reagent issue, every consumable drawn, every control consumed, and every repeat is already recorded against the work it produced. The actual cost of a reportable test is assembled from those real draws, not estimated. You set the expected cost for a test, and the system compares it against what each run actually consumed.
The output is not just a variance figure, it is a variance with its cause named: an over-issue, a higher reagent price, a run of repeats, or wastage. So instead of knowing only that a test cost more than planned, the lab knows why. That is the difference between a number that worries you and a number you can act on.
A planned cost tells you what should have happened. The stock draws tell you what did. You cannot manage the gap until you can see both, side by side, with the reason the gap exists.
The labs that get the most from this pair it with the variance flagging that surfaces the worst offenders automatically, so the few tests moving the number rise to the top on their own.
The reason expected-versus-actual works in Veona is that the actual cost is not a separate exercise. It reads the same books the lab already runs. There is no parallel spreadsheet to populate, no monthly reconciliation, no copy of the stock data that drifts away from the original. When a reagent price changes or stock is issued, the actual cost moves with it. The comparison stays live on its own, which is the only way a variance is useful: late variance is just history.
In a Nigerian laboratory, the most important variance is often the one driven by reagent price. Most reagents are imported and dollar-denominated, so a weakening naira raises the actual cost of a test while the expected cost, set weeks ago, stays put. Without an actual figure drawn from real stock draws, that erosion is invisible until it has already cut into the margin.
With expected and actual side by side, the lab sees the FX squeeze the moment it lands in the cost, named as a reagent-price driver rather than a mystery. It can reprice, renegotiate supply, or switch a product before the loss compounds. For a lab operating on thin margins in a volatile currency, that early sight is the difference between adjusting and absorbing. Read on for how to price a menu once you know the real cost.
See expected and actual cost compared from real stock draws, with the driver named. Book a demo and we will run the comparison on your own tests.
Ask most laboratories what a test costs and they will quote the reagent price. But a released result is the sum of many things, and the parts nobody counts are usually the ones eating the margin.
Margin rarely leaks evenly. A handful of tests, running far over what they should cost, usually drains more than the rest combined. The trick is finding them before they find your bottom line.
A reportable test is built from a recipe: reagents, the controls it shares, the wastage it carries, and a slice of overhead. Most labs know the first ingredient and guess at the rest.
We will tailor a demo to how your hospital, clinic, or lab actually runs, offline behaviour, payments, reporting, and all.